Profile: Medtronic PLC (MDT.N)
13 Jan 2017
Medtronic Public Limited Company (Medtronic), incorporated on June 12, 2014, is a medical technology, services and solutions company. The Company operates in four segments: Cardiac and Vascular Group, Minimally Invasive Therapies Group, Restorative Therapies Group and Diabetes Group. The Cardiac and Vascular Group segment includes cardiac rhythm and heart failure, coronary and structural heart, and aortic and peripheral vascular. Its Minimally Invasive Therapies Group segment includes surgical solutions, and patient monitoring and recovery. Its Restorative Therapies Group segment includes spine, neuromodulation, surgical technologies and neurovascular. Its Diabetes Group segment includes intensive insulin management, non-intensive diabetes therapies, and diabetes services and solutions. The Company's subsidiaries include Medtronic, Inc. and HeartWare International, Inc.
Cardiac and Vascular Group
The Company's Cardiac Rhythm & Heart Failure Disease Management (CRHF) division develops, manufactures and markets products for the diagnosis, treatment and management of heart rhythm disorders and heart failure. Its products include implantable devices, leads and delivery systems, products for the treatment of atrial fibrillation (AF), products designed to reduce surgical site infections, information systems for the management of patients with CRHF devices and an integrated health solutions business. The Company's Implantable Cardiac Pacemakers (Pacemakers) include Advisa MRI SureScan models, the Micra Transcatheter Pacing System and the Ensura MRI SureScan model. Its Implantable Cardioverter Defibrillators (ICDs) include Evera MRI SureScan.
The Company's Implantable Cardiac Resynchronization Therapy Devices (CRT-Ds and CRT-Ps) consist of CRT-Ds, which include Amplia/Compia/Claria family of MRI Quad CRT-D SureScan systems. The Viva/Brava family with Attain Performa quadripolar features an algorithm, which include AdaptivCRT that improves heart failure patients' response rate to CRT-D therapy. The Company's portfolio of AF products includes the Arctic Front Advance Cardiac Cryoballoon System, which consists of the Aortic Front Advance ST Cryoablation Catheter that is designed for pulmonary vein isolation in the treatment of patients with drug refractory paroxysmal AF. Its Reveal LINQ is its Insertable Cardiac Monitor (ICM) system. The Company's TYRX products include the Absorbable Antibacterial Envelope and the TYRX Neuro Absorbable Antibacterial Envelope, which are designed to stabilize electronic implantable devices and help prevent infection associated with implantable pacemakers, defibrillators and spinal cord neurostimulators. Its Cath Lab Managed Services business is focused on developing partnerships with hospitals to provide services directly related to hospital operational efficiency.
The Company's Coronary & Structural Heart Disease Management (CSH) division includes therapies to treat coronary artery disease (CAD) and heart valve disorders. Its products include coronary stents and related delivery systems, including a line of balloon angioplasty catheters, guide catheters, guide wires, diagnostic catheters and accessories, as well as products for the repair and replacement of heart valves, perfusion systems, positioning and stabilization systems for beating heart revascularization surgery and surgical ablation products. Its Transcatheter Heart Valves (TCVs) include the CoreValve family of aortic valves. It also includes recapturable TCV system and CoreValve Evolut R. Its Percutaneous Coronary Intervention (PCI) products include its Resolute Integrity drug-eluting stent systems and Resolute Onyx drug-eluting stent systems. It offers a line of surgical valve replacement and repair products for damaged or diseased heart valves. Its replacement products include both tissue and mechanical valves. It also offers a line of blood-handling products that form a circulatory support system to maintain and monitor blood circulation and coagulation status, oxygen supply and body temperature during arrested heart surgery. Additionally, it offers surgical ablation systems and positioning and stabilization technologies.
The Company's Aortic & Peripheral Vascular Disease Management (APV) division consists of a line of products and therapies to treat aortic disease, such as aneurysms, dissections and transections, as well as peripheral vascular disease (PVD) and critical limb ischemia (CLI). Its products include endovascular stent graft systems, peripheral drug coated balloon, stent and angioplasty systems, and carotid embolic protection systems for the treatment of vascular disease outside the heart. Its product line includes a range of endovascular stent grafts and accessories, including the Endurant 2S abdominal aortic aneurysm (AAA) stent graft system and the Valiant Captivia thoracic aortic aneurysm (TAA) stent graft system. Its primary Peripheral Vascular Intervention (PVI) products consist of percutaneous angioplasty balloons, including the IN.PACT family of drug-coated balloons, as well as peripheral stents, such as the the Protege & Complete Self Expanding Vascular Stents, the Visi-Pro & Assurant Cobalt Balloon Expandable stents, and directional atherectomy products, such as the TurboHawk plaque excision system, and other procedure support products. Its EndoVenous product lines are used to treat superficial and deep venous diseases in the lower extremities.
The Company competes with St. Jude Medical, Inc., Boston Scientific Corporation, Sorin Group, Edwards Lifesciences Corporation, C.R. Bard Inc. and Abbott Laboratories.
Minimally Invasive Therapies Group
The Company's Surgical Solutions division develops, manufactures and markets products and therapies to treat diseases and conditions that are addressed by surgeons. In addition, it develops, manufactures and markets several products in the fields of minimally invasive gastrointestinal diagnostics, ablation and interventional lung. Products offered by its Surgical Solutions division include surgical innovations and early technologies. Surgical Innovations business includes sales of stapling, vessel sealing, fixation (hernia mechanical devices), mesh, hardware and surgical instruments, sutures and electro surgery products. Its advanced surgical products include the Tri-Staple technology platform for endoscopic stapling; the iDrive and Signia powered stapling systems; the LigaSure vessel sealing system; the Sonicision cordless ultrasonic dissection system; AbsorbaTack absorbable mesh fixation; Symbotex composite mesh, and Parietex ProGrip. The Company's Early Technologies products include ablation products, and interventional lung and gastrointestinal solutions, including the PillCam SB and PillCam COLON; superDimesion to evaluate lung lesions; the Cool-tip radiofrequency ablation system; the Evident microwave ablation system, and the HALO ablation catheters.
The Company's Patient Monitoring & Recovery (PMR) division develops, manufactures and markets products and therapies to enable complication-free recovery to enhance patient outcomes. Products offered by its PMR division include patient monitoring, airway and ventilation, nursing care and patient care and safety (PCS). Its products include sensors, monitors, and temperature management products. Its patient monitoring products include Capnostream with Microstream technology capnography monitors, the Nellcor Bedside SpO2 patient monitoring system, the Bispectral Index (BIS) brain monitoring technology, the INVOS Cerebral/Somatic Oximeter, and related modules and sensors.
The Company's Airway and ventilation business includes sales of airway, ventilator and inhalation therapy products. Its airway and ventilation products include the Puritan Bennett 840 and 980 ventilators, the Newport e360 and HT70 ventilators, the TaperGuard Evac tube, Mallinckrodt Endotracheal Tubes, Shiley Tracheostomy Tubes, DAR Filters and resuscitation bags. Its Nursing Care business includes sales of incontinence, wound care, enteral feeding, urology and suction products. Its nursing care products include Curity and Kerlix gauze and bandages, and Kangaroo enteral feeding systems. Its patient care and safety (PCS) products include medical surgical products, such as operating room supply products, electrodes, and SharpSafety products, which include needles, syringes and sharps disposal products. Under its Medi-Trace brand, it offers a line of monitoring, diagnostic and defibrillation electrodes.
The Company competes with Johnson & Johnson, Boston Scientific Corporation, Baxter International Inc. and C.R. Bard Inc.
Restorative Therapies Group
The Company's Spine division develops, manufactures and markets a line of medical devices and implants used in the treatment of the spine and musculoskeletal system. Its products and therapies treat a range of conditions affecting the spine, including degenerative disc disease, spinal deformity, spinal tumors, fractures of the spine and stenosis. Its Spine division also provides biologic solutions for the orthopedic and dental markets and, in concert with its Surgical Technologies business, it offers navigation, neuromonitoring and power technologies designed for spine procedures.
The Company's Thoracolumbar products used to treat conditions in the region of the spine include the CD HORIZON SOLERA and LEGACY Systems, and the CAPSTONE and CLYDESDALE interbody spacers. In addition, Medtronic offers CD HORIZON VOYAGER, SOLERA SEXTANT and LONGITUDE Percutaneous Fixation Systems.
Cervical products used to treat conditions in the region of the spine include ZEVO and ATLANTIS VISION ELITE Anterior Cervical Plate Systems, the VERTEX SELECT Reconstruction System, and the PRESTIGE and BRYAN Cervical Artificial Discs. The Company's Biologics platform products include INFUSE Bone Graft, which contains a recombinant human bone morphogenetic protein, rhBMP-2, for certain spinal, trauma and oral maxillofacial applications; Demineralized Bone Matrix (DBM) products, including MagniFuse, Grafton/Grafton Plus, and PROGENIX, and the MASTERGRAFT family of synthetic bone graft products, which include Matrix, Putty and Granules. Its interventional products include the Xpander II Balloon Kyphoplasty system, the Kyphon-V vertebroplastly system and the Osteocool tumor ablation system.
The Company's Neuromodulation division includes implantable neurostimulation and targeted drug delivery systems for the management of chronic pain, common movement disorders, spasticity, and urologic and gastrointestinal disorders. It has a portfolio of neurostimulation systems, including rechargeable and non-rechargeable devices, and a selection of leads used to treat chronic back and/or limb pain. Its portfolio of products include pain neurostimulation systems with SureScan MRI Technology, including the RestoreSensor (rechargeable) SureScan MRI, with its AdaptiveStim technology. Its SynchroMed II Implantable Infusion System delivers small quantities of drug directly into the intrathecal space surrounding the spinal cord. These devices are used to treat chronic, intractable pain and severe spasticity associated with cerebral palsy, multiple sclerosis, spinal cord and traumatic brain injuries, and stroke.
Deep Brain Stimulation (DBS) Systems are approved in various countries around the world for the treatment of the disabling symptoms of essential tremor, Parkinson's disease, refractory epilepsy, severe, treatment-resistant obsessive-compulsive disorder, and chronic and intractable primary dystonia. Its family of Activa Neurostimulators for DBS includes Activa single-channel primary cell battery (SC), Activa dual channel primary cell battery (PC) and Activa dual channel rechargeable battery (RC). Its Sacral neuromodulation uses InterStim, a neurostimulator, to help control the symptoms of overactive bladder, (non-obstructive) urinary retention and chronic fecal incontinence. Enterra Therapy is the gastric electrical stimulation therapy for use in the treatment of intractable nausea and vomiting associated with gastroparesis.
The Company's Surgical Technologies division develops, manufactures and markets products and therapies to treat diseases and conditions of the ear, nose and throat (ENT), and certain neurological disorders. In addition, the division develops, manufactures and markets image-guided surgery and intra-operative imaging systems that facilitate surgical planning during precision cranial, spinal, sinus and orthopedic surgeries. Its Advanced Energy business includes products in the field of advanced energy surgical incision technology, as well as the hemostatic sealing of soft tissue and bone. Its neurosurgery consists of products, which include both platform technologies and implant therapies. The StealthStation Navigation System and O-arm Imaging System are both platforms used in cranial, spinal, sinus and orthopedic procedures. The Midas Rex Surgical Drills are used in cranial, spinal and orthopedic procedures. Visualase MRI-Guided Laser Ablation is used in neurosurgery procedures.
The Company's products that treat ENT diseases and conditions include Straightshot M5 Microdebrider Handpiece, NIM Nerve Monitoring Systems, Fusion ENT Navigation System, as well as products for hearing restoration, and snoring and obstructive sleep apnea. The Company's PEAK Surgery System is a tissue dissection system that consists of the PEAK PlasmaBlade and PULSAR Generator. Its Aquamantys System uses transcollation technology to provide hemostatic sealing of soft tissue and bone and is cleared for use in a range of surgical procedures, including orthopedic surgery, spine, solid organ resection and thoracic procedures.
The Company's Neurovascular division develops, manufactures and markets products and therapies to treat diseases of the vasculature in and around the brain. Its products include coils, neurovascular stents and flow diversion products, as well as access and delivery products to support procedures. The products offered by the Company's Neurovascular division include the Pipeline and Pipeline Flex Embolization Devices; endovascular treatments for large or giant wide-necked brain aneurysms; the Solitaire FR revascularization device for treatment of acute ischemic stroke, and the Apollo Onyx delivery micro catheter.
The Company competes with Johnson & Johnson, Boston Scientific Corporation, St. Jude Medical, Inc., Stryker Corporation, NuVasive, Inc. and Zimmer Holdings, Inc.
The Company's Diabetes group consists of divisions, which include Intensive Insulin Management, Non-Intensive Diabetes Therapies, and Diabetes Services & Solutions. The Diabetes group's divisions develop, manufacture, and market integrated diabetes management solutions that include insulin pump therapy, continuous glucose monitoring (CGM) systems and therapy management software.
In the United States, the Company offers the MiniMed 530G System featuring SmartGuard technology, which automatically suspends insulin delivery when glucose levels reach a pre-determined threshold, and a CGM sensor, Enlite, which is a sensor that can be worn for approximately six days. Outside the United States, the Company offers its MiniMed 640G System, which is an integrated system with the Enhanced Enlite CGM sensor that features SmartGuard technology, which automatically suspends insulin delivery when sensor glucose levels are predicted to approach a low limit and then resumes insulin delivery once levels recover. In addition to the Company's Personal CGM (Enlite), it offers physicians a Professional CGM product called the iPro2/iPro Professional CGM System. It also offers connected care solutions, including the MiniMed Connect. Its Web-based therapy management software solutions include CareLink Personal software for patients and CareLink Pro software.
The Company competes with Johnson & Johnson, DexCom, Inc., Tandem Diabetes Care Inc., Insulet Corporation and F. Hoffmann-La Roche Ltd.
20 On Hatch, Hatch Street Lower
Company Web Links
- Medtronic must face revived U.S. lawsuit over Infuse
- Abbott gets U.S. antitrust approval to buy St. Jude Medical |
- China says fines Medtronic local unit $17.2 million for price fixing
- BRIEF-Medtronic announces U.S. launch of integrated health solutions
- BRIEF-Medtronic first to receive european approval for less-invasive HVAD implant procedure